See more : Aikchol Hospital Public Company Limited (AHC.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Oxurion NV (TBGNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oxurion NV, a leading company in the Biotechnology industry within the Healthcare sector.
- Cascade Acquisition Corp. (CAS) Income Statement Analysis – Financial Results
- Cipla Limited (CIPLA.NS) Income Statement Analysis – Financial Results
- ACRO Biomedical Co., Ltd. (6748.TWO) Income Statement Analysis – Financial Results
- Idaho Strategic Resources, Inc. (IDR) Income Statement Analysis – Financial Results
- iSelect Limited (ISU.AX) Income Statement Analysis – Financial Results
Oxurion NV (TBGNF)
About Oxurion NV
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Source: https://incomestatements.info
Category: Stock Reports